U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 3 of 3 results

Status:
US Approved Rx (2019)
First approved in 2001

Class (Stereo):
CHEMICAL (ACHIRAL)



Bosentan is a dual endothelin receptor antagonist important in the treatment of pulmonary artery hypertension (PAH). It is licensed in the United States, the European Union and other countries by Actelion Pharmaceuticals for the management of PAH und...
Status:
US Approved Rx (2019)
First approved in 2001

Class (Stereo):
CHEMICAL (ACHIRAL)



Bosentan is a dual endothelin receptor antagonist important in the treatment of pulmonary artery hypertension (PAH). It is licensed in the United States, the European Union and other countries by Actelion Pharmaceuticals for the management of PAH und...
Status:
US Approved Rx (2019)
First approved in 2001

Class (Stereo):
CHEMICAL (ACHIRAL)



Bosentan is a dual endothelin receptor antagonist important in the treatment of pulmonary artery hypertension (PAH). It is licensed in the United States, the European Union and other countries by Actelion Pharmaceuticals for the management of PAH und...